Sunjae Bae1,2, Mara A McAdams-DeMarco1,2, Allan B Massie1,2, JiYoon B Ahn1, William A Werbel3, Daniel C Brennan3, Krista L Lentine4, Christine M Durand3,5, Dorry L Segev1,2. 1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD. 3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Center for Abdominal Transplantation, Saint Louis University, St. Louis, MO. 5. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Kidney transplant recipients have higher risk of infectious diseases due to their reliance on immunosuppression. During the current COVID-19 pandemic, some clinicians might have opted for less potent immunosuppressive agents to counterbalance the novel infectious risk. We conducted a nationwide study to characterize immunosuppression use and subsequent clinical outcomes during the first 5 months of COVID-19 pandemic in the United States. METHODS: Using data from the Scientific Registry of Transplant Recipients, we studied all kidney-only recipients in the United States from January 1, 2017, to March 12, 2020 ("prepandemic" era; n = 64 849) and from March 13, 2020, to July 31, 2020 ("pandemic" era; n = 5035). We compared the use of lymphocyte-depleting agents (versus basiliximab or no induction) and maintenance steroids (versus steroid avoidance/withdrawal) in the pandemic era compared with the prepandemic era. Then, we compared early posttransplant outcomes by immunosuppression regimen during the pandemic era. RESULTS: Recipients in the pandemic era were substantially less likely to receive lymphocyte-depleting induction agents compared with their prepandemic counterparts (aOR = 0.400.530.69); similar trends were found across subgroups of state-level COVID-19 incidence, donor type, and recipient age. However, lymphocyte-depleting induction agents were associated with decreased rejection during admission (aOR = 0.110.230.47) but not with increased mortality in the pandemic era (aHR = 0.130.471.66). On the other hand, the use of maintenance steroids versus early steroid withdrawal remained similar (aOR = 0.711.071.62). CONCLUSIONS: The use of lymphocyte-depleting induction agents has decreased in favor of basiliximab and no induction during the COVID-19 pandemic. However, this shift might have resulted in increases in rejection with no clear reductions in posttransplant mortality.
BACKGROUND: Kidney transplant recipients have higher risk of infectious diseases due to their reliance on immunosuppression. During the current COVID-19 pandemic, some clinicians might have opted for less potent immunosuppressive agents to counterbalance the novel infectious risk. We conducted a nationwide study to characterize immunosuppression use and subsequent clinical outcomes during the first 5 months of COVID-19 pandemic in the United States. METHODS: Using data from the Scientific Registry of Transplant Recipients, we studied all kidney-only recipients in the United States from January 1, 2017, to March 12, 2020 ("prepandemic" era; n = 64 849) and from March 13, 2020, to July 31, 2020 ("pandemic" era; n = 5035). We compared the use of lymphocyte-depleting agents (versus basiliximab or no induction) and maintenance steroids (versus steroid avoidance/withdrawal) in the pandemic era compared with the prepandemic era. Then, we compared early posttransplant outcomes by immunosuppression regimen during the pandemic era. RESULTS: Recipients in the pandemic era were substantially less likely to receive lymphocyte-depleting induction agents compared with their prepandemic counterparts (aOR = 0.400.530.69); similar trends were found across subgroups of state-level COVID-19 incidence, donor type, and recipient age. However, lymphocyte-depleting induction agents were associated with decreased rejection during admission (aOR = 0.110.230.47) but not with increased mortality in the pandemic era (aHR = 0.130.471.66). On the other hand, the use of maintenance steroids versus early steroid withdrawal remained similar (aOR = 0.711.071.62). CONCLUSIONS: The use of lymphocyte-depleting induction agents has decreased in favor of basiliximab and no induction during the COVID-19 pandemic. However, this shift might have resulted in increases in rejection with no clear reductions in posttransplant mortality.
Authors: Sunjae Bae; Jacqueline M Garonzik Wang; Allan B Massie; Kyle R Jackson; Mara A McAdams-DeMarco; Daniel C Brennan; Krista L Lentine; Josef Coresh; Dorry L Segev Journal: J Am Soc Nephrol Date: 2019-12-18 Impact factor: 10.121
Authors: Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland Journal: N Engl J Med Date: 2010-11-18 Impact factor: 91.245
Authors: E Steve Woodle; M Roy First; John Pirsch; Fuad Shihab; A Osama Gaber; Paul Van Veldhuisen Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Stephen M Kissler; Christine Tedijanto; Yonatan H Grad; Marc Lipsitch; Edward Goldstein Journal: Science Date: 2020-04-14 Impact factor: 47.728
Authors: Matthew J Weiss; Laura Hornby; Farid Foroutan; Sara Belga; Simon Bernier; Mamatha Bhat; C Arianne Buchan; Michael Gagnon; Gillian Hardman; Maria Ibrahim; Cindy Luo; Me-Linh Luong; Rahul Mainra; Alex R Manara; Ruth Sapir-Pichhadze; Sarah Shalhoub; Tina Shaver; Jeffrey M Singh; Sujitha Srinathan; Ian Thomas; Lindsay C Wilson; T Murray Wilson; Alissa Wright; Allison Mah Journal: Transplant Direct Date: 2021-09-07
Authors: Emily Lauren Simms; Hyunjae Chung; Lisa Oberding; Daniel A Muruve; Braedon McDonald; Amy Bromley; Dylan R Pillai; Justin Chun Journal: Am J Transplant Date: 2021-03-15 Impact factor: 9.369